{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-014289","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.072212+00:00","generated_at":"2026-05-30T00:37:08.314186+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dermata nears completion of DMT310 Phase 3 enrollment; Q3 2024 cash at $6.1M","bullets":["Enrollment in DMT310 Phase 3 STAR-1 acne trial expected to complete by end of 2024; topline results Q1 2025.","Cash and equivalents of $6.1M at Sep 30, 2024; expected to fund operations into Q2 2025.","Raised $7.8M in gross proceeds during 2024, including $5.1M in Q3 2024.","R&D expenses $2.4M in Q3 2024, up from $0.9M due to STAR-1 clinical trial costs.","G&A expenses $0.8M in Q3 2024, down from $0.9M in Q3 2023 on lower insurance costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-014289","json":"https://secwatch.observer/filing/0001654954-24-014289.json","markdown":"https://secwatch.observer/filing/0001654954-24-014289.md","text":"https://secwatch.observer/filing/0001654954-24-014289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424014289/0001654954-24-014289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424014289/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:37:08.314186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}